|
ES2560871T3
(es)
|
2007-07-10 |
2016-02-23 |
Apogenix Gmbh |
Proteínas de fusión de colectina de la superfamilia de TNF
|
|
WO2010003766A2
(en)
*
|
2008-06-17 |
2010-01-14 |
Apogenix Gmbh |
Multimeric tnf receptors
|
|
WO2010006772A2
(en)
*
|
2008-07-14 |
2010-01-21 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Use of cd95 inhibitors for the treatment of inflammatory disorders
|
|
ES2538122T3
(es)
|
2008-07-21 |
2015-06-17 |
Apogenix Gmbh |
Moléculas de una sola cadena de TNFSF
|
|
US8664366B2
(en)
|
2009-01-09 |
2014-03-04 |
Apogenix Gmbh |
Fusion proteins forming trimers
|
|
TWI476001B
(zh)
|
2011-12-26 |
2015-03-11 |
Ind Tech Res Inst |
三倍體Fc融合蛋白及其用途
|
|
BR112015001390B1
(pt)
|
2012-07-26 |
2024-04-30 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc |
Proteína de fusão, ácido nucleico isolado e uso de uma composição de vacina
|
|
WO2014100913A1
(en)
*
|
2012-12-24 |
2014-07-03 |
Beijing Anxinhuaide Biotech. Co., Ltd |
Improving the half life of a therapeutic polypeptide by fusing with a trimeric scaffold protein via a spacer
|
|
NO2776305T3
(https=)
|
2014-04-23 |
2018-01-27 |
|
|
|
BR102014031185A8
(pt)
*
|
2014-12-12 |
2021-05-04 |
Fund De Amparo A Pesquisa Do Estado De Sao Paulo Fapesp |
proteína recombinante indutora da apoptose; processo de obtenção da dita proteína e o seu uso no tratamento do câncer
|
|
IL308212A
(en)
|
2015-01-20 |
2024-01-01 |
Igm Biosciences Inc |
Tumor necrosis factor-α receptor binding molecules and their uses
|
|
MA41460A
(fr)
|
2015-02-03 |
2017-12-12 |
Oncomed Pharm Inc |
Agents de liaison à la tnfrsf et leurs utilisations
|
|
EP3076179A1
(en)
|
2015-03-30 |
2016-10-05 |
Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts |
Diagnosis and treatment of low grade gliomas
|
|
CN108290950B
(zh)
|
2015-09-23 |
2022-01-28 |
阿珀吉科吉尼科斯股份公司 |
抗cd95l抗体
|
|
EP3374504B1
(en)
*
|
2015-11-09 |
2025-03-19 |
CureVac SE |
Optimized nucleic acid molecules
|
|
TWI788307B
(zh)
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
|
|
MX2019007963A
(es)
|
2017-01-06 |
2019-10-21 |
Iovance Biotherapeutics Inc |
Expansion de linfocitos infiltrantes de tumor (til) con agonistas de la superfamilia de recptor de factor de necrosis tumoral (tnfrsf) y combinaciones terapeuticas de til- y agonistas de tnfrsf.
|
|
CA3049165A1
(en)
|
2017-01-06 |
2018-07-12 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
|
|
KR20200003913A
(ko)
|
2017-05-10 |
2020-01-10 |
이오반스 바이오테라퓨틱스, 인크. |
액상 종양으로부터의 종양 침윤 림프구의 확장 및 그의 치료 용도
|
|
AR112072A1
(es)
|
2017-06-05 |
2019-09-18 |
Iovance Biotherapeutics Inc |
Métodos de uso de linfocitos infiltrantes de tumor en melanoma doble refractario
|
|
JP7744621B2
(ja)
*
|
2017-08-11 |
2025-09-26 |
ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイ |
切断されたモルモットl-アスパラギナーゼバリアントおよび使用の方法
|
|
CR20200251A
(es)
|
2017-11-17 |
2020-07-17 |
Iovance Biotherapeutics Inc |
Expansión de til de aspirados con aguja fina y biopsias por punción
|
|
EP3714041A1
(en)
|
2017-11-22 |
2020-09-30 |
Iovance Biotherapeutics, Inc. |
Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
|
|
US20210369775A1
(en)
|
2017-12-15 |
2021-12-02 |
Iovance Biotherapeutics, Inc. |
Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof
|
|
WO2019136459A1
(en)
|
2018-01-08 |
2019-07-11 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products enriched for tumor antigen-specific t-cells
|
|
US11713446B2
(en)
|
2018-01-08 |
2023-08-01 |
Iovance Biotherapeutics, Inc. |
Processes for generating TIL products enriched for tumor antigen-specific T-cells
|
|
EP3737743A1
(en)
|
2018-01-08 |
2020-11-18 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products enriched for tumor antigen-specific t-cells
|
|
CA3090795A1
(en)
|
2018-02-13 |
2019-08-22 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes (tils) with adenosine a2a receptor antagonists and therapeutic combinations of tils and adenosine a2a receptor antagonists
|
|
CA3094957A1
(en)
|
2018-03-29 |
2019-10-03 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
WO2019210131A1
(en)
|
2018-04-27 |
2019-10-31 |
Iovance Biotherapeutics, Inc. |
Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
WO2019217753A1
(en)
|
2018-05-10 |
2019-11-14 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
WO2020018715A1
(en)
|
2018-07-17 |
2020-01-23 |
Massachusetts Institute Of Technology |
Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof
|
|
TW202031273A
(zh)
|
2018-08-31 |
2020-09-01 |
美商艾歐凡斯生物治療公司 |
抗pd-1抗體難治療性之非小細胞肺癌(nsclc)病患的治療
|
|
IL281423B2
(en)
|
2018-09-20 |
2024-08-01 |
Iovance Biotherapeutics Inc |
Expansion of TILS from cryopreserved tumor samples
|
|
WO2020096927A1
(en)
|
2018-11-05 |
2020-05-14 |
Iovance Biotherapeutics, Inc. |
Expansion of tils utilizing akt pathway inhibitors
|
|
MY210603A
(en)
|
2018-11-05 |
2025-10-01 |
Iovance Biotherapeutics Inc |
Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
|
|
US12611427B2
(en)
|
2018-11-05 |
2026-04-28 |
Iovance Biotherapeutics, Inc. |
Treatment of NSCLC patients refractory for anti-PD-1 antibody
|
|
JP7854297B2
(ja)
|
2018-11-05 |
2026-05-01 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
改良された腫瘍反応性t細胞の選択
|
|
CA3123392A1
(en)
|
2018-12-19 |
2020-06-25 |
Iovance Biotherapeutics, Inc. |
Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof
|
|
WO2020180733A1
(en)
|
2019-03-01 |
2020-09-10 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
|
US20220177841A1
(en)
|
2019-03-29 |
2022-06-09 |
Myst Therapeutics Llc |
Ex vivo methods for producing a t cell therapeutic and related compositions and methods
|
|
WO2020232029A1
(en)
|
2019-05-13 |
2020-11-19 |
Iovance Biotherapeutics, Inc. |
Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
|
|
EP4048295A1
(en)
|
2019-10-25 |
2022-08-31 |
Iovance Biotherapeutics, Inc. |
Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
US20230032934A1
(en)
|
2019-11-27 |
2023-02-02 |
Myst Therapeutics, Llc |
Method of producing tumor-reactive t cell composition using modulatory agents
|
|
US12516291B2
(en)
|
2019-12-11 |
2026-01-06 |
Iovance Biotherapeutics, Inc. |
Processes for the production of tumor infiltrating lymphocytes (TILs) and methods of using the same
|
|
EP4512828A3
(en)
|
2020-02-27 |
2025-05-14 |
Turnstone Biologics Corp. |
Methods for ex vivo enrichment and expansion of tumor reactive t cells and related compositions thereof
|
|
CA3176826A1
(en)
|
2020-05-04 |
2021-11-11 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
|
|
CA3177413A1
(en)
|
2020-05-04 |
2021-11-11 |
Michelle SIMPSON-ABELSON |
Selection of improved tumor reactive t-cells
|
|
US20240016918A1
(en)
*
|
2020-08-24 |
2024-01-18 |
Sanofi Pasteur Inc. |
Vaccines against sars-cov-2 infections
|
|
WO2022076606A1
(en)
|
2020-10-06 |
2022-04-14 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
|
JP2023546359A
(ja)
|
2020-10-06 |
2023-11-02 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
腫瘍浸潤リンパ球療法によるnsclc患者の治療
|
|
EP4259164A1
(en)
|
2020-12-11 |
2023-10-18 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors
|
|
EP4262827A1
(en)
|
2020-12-17 |
2023-10-25 |
Iovance Biotherapeutics, Inc. |
Treatment of cancers with tumor infiltrating lymphocytes
|
|
AU2021401302A1
(en)
|
2020-12-17 |
2023-07-06 |
Iovance Biotherapeutics, Inc. |
Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
|
|
CA3207359A1
(en)
|
2021-02-05 |
2022-08-11 |
Cecile Chartier-Courtaud |
Adjuvant therapy for cancer
|
|
EP4301138A2
(en)
|
2021-03-05 |
2024-01-10 |
Iovance Biotherapeutics, Inc. |
Tumor storage and cell culture compositions
|
|
JP2024512029A
(ja)
|
2021-03-25 |
2024-03-18 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
T細胞共培養効力アッセイのための方法及び組成物、ならびに細胞療法製品との使用
|
|
CA3215830A1
(en)
|
2021-04-19 |
2022-10-27 |
Rafael CUBAS |
Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
|
|
JP2024519029A
(ja)
|
2021-05-17 |
2024-05-08 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
Pd-1遺伝子編集された腫瘍浸潤リンパ球及び免疫療法におけるその使用
|
|
KR20240013766A
(ko)
*
|
2021-05-27 |
2024-01-30 |
베이징 안신화이더 바이오텍. 씨오., 엘티디 |
2개의 trail 삼량체를 포함하는 수퍼-trail 분자
|
|
JP2024527961A
(ja)
|
2021-07-28 |
2024-07-26 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
Kras阻害剤と併用した腫瘍浸潤リンパ球療法によるがん患者の治療
|
|
US20250000903A1
(en)
|
2021-09-24 |
2025-01-02 |
Iovance Biotherapeutics, Inc. |
Expansion processes and agents for tumor infiltrating lymphocytes
|
|
WO2023077015A2
(en)
|
2021-10-27 |
2023-05-04 |
Iovance Biotherapeutics, Inc. |
Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
|
|
CA3237410A1
(en)
|
2021-11-10 |
2023-05-19 |
Friedrich Graf Finck VON FINCKENSTEIN |
Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
|
|
CA3243416A1
(en)
|
2022-01-28 |
2023-08-03 |
Iovance Biotherapeutics, Inc. |
TUMOR INFILTRATION LYMPHOCYTES MODIFIED TO EXPRESS PAYLOADS
|
|
JP2025512401A
(ja)
|
2022-04-15 |
2025-04-17 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
特定のサイトカインの組み合わせ及び/またはAKTi処理を使用したTIL拡張プロセス
|
|
US20260021181A1
(en)
|
2022-08-01 |
2026-01-22 |
Iovance Biotherapeutics, Inc. |
Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
|
|
WO2024098024A1
(en)
|
2022-11-04 |
2024-05-10 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
|
WO2024151885A1
(en)
|
2023-01-13 |
2024-07-18 |
Iovance Biotherapeutics, Inc. |
Use of til as maintenance therapy for nsclc patients who achieved pr/cr after prior therapy
|
|
WO2025101484A1
(en)
|
2023-11-06 |
2025-05-15 |
Iovance Biotherapeutics, Inc. |
Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies
|